Publications: Risk Factors: Molecular Therapy/Molecular Markers


2002
1. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin Y, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR.  Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870): 436-442, 2002.

2001
2. Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, Alzamora MG, Louis DN, Stiles CD, Rowitch DH, Black PM.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors.  Proc Natl Acad Sci U.S.A. , 98(19):10851-10856, 2001.

3. Joki T, Carroll RS, Dunn IF, Zhang J, Abe T, Black PM.  Assessment of Alterations in Gene Expression in Recurrent Malignant Gliomas After Radiotherapy Using Complementary Deoxyribonucleic Acid Microarrays.  Neurosurgery, 48(1): 195-202, 2001.

2000
4. Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C.  Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population.  J Med Genet, 37(6): 410-414, 2000.

1998
Zhu JJ, Santarius T, Wu X, Tsong J, Guha A, Wu JK, Hudson TJ, Black PM.  Screening for Loss of Heterozygosity and Microsatellite Instability in Oligodendrogliomas.  Genes Chromosomes Cancer, 21(3): 207-216, 1998.

1996
Zhu J, Guo SZ, Beggs AH, Maruyama T, Santarius T, Dashner K, Olsen N, Wu JK, Black PM. Microsatellite instability analysis of primary human brain tumors. Oncogene, 12(7): 1417-1423, 1996.

1993
Leon S, Zhu J, Black PM. Genetic Aberrations in Human Brain Tumors. Neurosurgery 1993; 34:708-722.